Global Peptide Therapeutics Market & Clinical Trials Insight 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:
Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.
Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.
Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.
Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.
“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:
- Fundamentals of Peptide Therapeutics
- Peptide Therapeutics by Applications & Indications
- Peptides Clinical Trials Insight by Phase, Indication & Company
- Insight on 688 Peptide Drugs in Clinical Trials
- Clinical & Patent Insight on 119 Marketed Peptides
- Future Peptide Therapeutics Market Outlook
Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.
Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.
Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.
Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.
1. A REVOLUTION OF PEPTIDE THERAPEUTICS
1.1 Peptides as Drug Candidates
1.2 Necessity of Peptide Therapeutics
2. CUSP OF SMALL MOLECULES & PROTEINS
2.1 Peptides v/s Small Molecules
2.2 Peptides v/s Protein Biologics
3. FUNDAMENTALS OF PEPTIDE THERAPEUTICS
3.1 Rational Design for Novel Peptides
3.2 Aspects of Regulatory Approvals
4. PEPTIDE THERAPEUTICS BY APPLICATIONS
4.1 Application of Peptides in Imaging
4.2 Application of Peptides in Diseases
5. PEPTIDE THERAPEUTICS IN METABOLIC DISORDER
5.1 Prologue Metabolic Disorders
5.2 Approved Peptide Drugs for Metabolic Disorders
5.3 Market of Metabolic Peptides
6. PEPTIDE THERAPEUTICS IN CANCER
6.1 Prologue to Cancer
6.2 Approved Peptide Drugs in Cancer Therapeutics
6.3 Market of Cancer Peptides
7. PEPTIDE THERAPEUTICS IN CARDIOVASCULAR
7.1 Prologue to Cardiovascular Diseases
7.2 Approved Peptide Drugs in Cardiovascular Diseases
7.3 Market of Cardiac Peptides
8. PEPTIDE THERAPEUTICS IN HIV & INFECTIONS
8.1 Prologue to Infections
8.2 Approved Peptide Therapeutics in Infections
8.3 Market of Anti-Infectious Peptides
9. PEPTIDE THERAPEUTICS IN CNS DISORDERS
9.1 Prologue to CNS Disorders
9.2 Neuropeptides Drug Delivery to CNS
9.3 Future Market Potential
10. GLOBAL PEPTIDE THERAPEUTICS MARKET
10.1 Prologue to the Peptide Market
10.2 Peptide Market by Application
11. GLOBAL PEPTIDE MARKET BY ADMINISTRATION
11.1 Current Trends in Route of Administration
11.2 Current Trends over the Peptide Products
12. GLOBAL PEPTIDES CLINICAL TRIALS OVERVIEW
12.1 Cyclic Peptides
12.2 Depsipeptides
12.3 Dipeptides
12.4 Glucagon-Like Peptides
12.5 Lipopeptides
12.6 Natriuretic Peptides
12.7 Neuropeptides Peptides
12.8 Oligopeptides
12.9 Opioid Peptides
12.10 Peptides
12.11 Peptide Hormones
12.12 Peptide Fragments
12.13 Multiple Peptides
13. GLOBAL PEPTIDE MARKET BY REGION
13.1 North America
13.2 Europe
13.3 Asia
14. GLOBAL PEPTIDE MARKET DYNAMICS
14.1 Favorable Parameters
14.2 Challenges
15. FUTURE PEPTIDE THERAPEUTICS MARKET OUTLOOK
15.1 Future Trends in Peptide Therapeutics
15.2 Future Opportunities of Peptides Therapeutics
16. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
16.1 Research till Preregistration
16.2 Marketed
17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
17.1 Preclinical till Preregistration
17.2 Marketed
18. DIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
18.1 Preclinical till Registered
18.2 Marketed
19. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
19.1 Preclinical till Phase-I
20. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
20.1 Resarch till Phase-III
20.2 Marketed
21. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
21.1 Preclinical till Phase-II
22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
22.1 Preclinical till Phase-III
22.2 Marketed
23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
23.1 Preclinical till Phase-III
23.2 Marketed
24. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
24.1 Preclinical till Registered
24.2 Marketed
25. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
25.1 Preclinical till Preregistration
25.2 Marketed
26. PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
26.1 Research till Registered
26.2 Marketed
27. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
27.1 Research
28. PEPTIDE APTAMERS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
28.1 Preclinical
29. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
29.1 Research till Registered
29.2 Marketed
30. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
30.1 Research till Preregistration
30.2 Marketed
31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
31.1 Research till Preregistration
31.2 Marketed
32. COMPETITIVE LANDSCAPE
32.1 Amgen
32.2 Amylin Pharmaceuticals
32.3 Apitope Technology
32.4 BioPartners
32.5 BiondVax Pharmaceuticals Ltd
32.6 Boehringer Ingelheim
32.7 Circassia
32.8 Corden Pharma (Peptisyntha)
32.9 Eli Lily
32.10 Galena Biopharmaceuticals
32.11 GlaxoSmithKline
32.12 Hyperion Therapeutics
32.13 ImmunoCellular Therapeutics
32.14 Ipsen
32.15 Lonza
32.16 Merck
32.17 NovoNordisk
32.18 Par Pharmaceuticals
32.19 PeptiDream
32.20 Roche
32.21 Sanofi
32.22 Tarix Pharmaceuticals
1.1 Peptides as Drug Candidates
1.2 Necessity of Peptide Therapeutics
2. CUSP OF SMALL MOLECULES & PROTEINS
2.1 Peptides v/s Small Molecules
2.2 Peptides v/s Protein Biologics
3. FUNDAMENTALS OF PEPTIDE THERAPEUTICS
3.1 Rational Design for Novel Peptides
3.2 Aspects of Regulatory Approvals
4. PEPTIDE THERAPEUTICS BY APPLICATIONS
4.1 Application of Peptides in Imaging
4.2 Application of Peptides in Diseases
5. PEPTIDE THERAPEUTICS IN METABOLIC DISORDER
5.1 Prologue Metabolic Disorders
5.2 Approved Peptide Drugs for Metabolic Disorders
5.3 Market of Metabolic Peptides
6. PEPTIDE THERAPEUTICS IN CANCER
6.1 Prologue to Cancer
6.2 Approved Peptide Drugs in Cancer Therapeutics
6.3 Market of Cancer Peptides
7. PEPTIDE THERAPEUTICS IN CARDIOVASCULAR
7.1 Prologue to Cardiovascular Diseases
7.2 Approved Peptide Drugs in Cardiovascular Diseases
7.3 Market of Cardiac Peptides
8. PEPTIDE THERAPEUTICS IN HIV & INFECTIONS
8.1 Prologue to Infections
8.2 Approved Peptide Therapeutics in Infections
8.3 Market of Anti-Infectious Peptides
9. PEPTIDE THERAPEUTICS IN CNS DISORDERS
9.1 Prologue to CNS Disorders
9.2 Neuropeptides Drug Delivery to CNS
9.3 Future Market Potential
10. GLOBAL PEPTIDE THERAPEUTICS MARKET
10.1 Prologue to the Peptide Market
10.2 Peptide Market by Application
11. GLOBAL PEPTIDE MARKET BY ADMINISTRATION
11.1 Current Trends in Route of Administration
11.2 Current Trends over the Peptide Products
12. GLOBAL PEPTIDES CLINICAL TRIALS OVERVIEW
12.1 Cyclic Peptides
12.2 Depsipeptides
12.3 Dipeptides
12.4 Glucagon-Like Peptides
12.5 Lipopeptides
12.6 Natriuretic Peptides
12.7 Neuropeptides Peptides
12.8 Oligopeptides
12.9 Opioid Peptides
12.10 Peptides
12.11 Peptide Hormones
12.12 Peptide Fragments
12.13 Multiple Peptides
13. GLOBAL PEPTIDE MARKET BY REGION
13.1 North America
13.2 Europe
13.3 Asia
14. GLOBAL PEPTIDE MARKET DYNAMICS
14.1 Favorable Parameters
14.2 Challenges
15. FUTURE PEPTIDE THERAPEUTICS MARKET OUTLOOK
15.1 Future Trends in Peptide Therapeutics
15.2 Future Opportunities of Peptides Therapeutics
16. CYCLIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
16.1 Research till Preregistration
16.2 Marketed
17. DEPSIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
17.1 Preclinical till Preregistration
17.2 Marketed
18. DIPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
18.1 Preclinical till Registered
18.2 Marketed
19. GLYCOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
19.1 Preclinical till Phase-I
20. GLUCAGON-LIKE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
20.1 Resarch till Phase-III
20.2 Marketed
21. LIPOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
21.1 Preclinical till Phase-II
22. NATRIURETIC PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
22.1 Preclinical till Phase-III
22.2 Marketed
23. NEUROPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
23.1 Preclinical till Phase-III
23.2 Marketed
24. OLIGOPEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
24.1 Preclinical till Registered
24.2 Marketed
25. OPIOID PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
25.1 Preclinical till Preregistration
25.2 Marketed
26. PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
26.1 Research till Registered
26.2 Marketed
27. PEPTIDE ANTIBIOTICS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
27.1 Research
28. PEPTIDE APTAMERS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
28.1 Preclinical
29. PEPTIDE HORMONES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
29.1 Research till Registered
29.2 Marketed
30. PEPTIDE FRAGMENTS CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
30.1 Research till Preregistration
30.2 Marketed
31. MULTIPLE PEPTIDES CLINICAL TRIALS INSIGHT BY PHASE, INDICATION & COMPANY
31.1 Research till Preregistration
31.2 Marketed
32. COMPETITIVE LANDSCAPE
32.1 Amgen
32.2 Amylin Pharmaceuticals
32.3 Apitope Technology
32.4 BioPartners
32.5 BiondVax Pharmaceuticals Ltd
32.6 Boehringer Ingelheim
32.7 Circassia
32.8 Corden Pharma (Peptisyntha)
32.9 Eli Lily
32.10 Galena Biopharmaceuticals
32.11 GlaxoSmithKline
32.12 Hyperion Therapeutics
32.13 ImmunoCellular Therapeutics
32.14 Ipsen
32.15 Lonza
32.16 Merck
32.17 NovoNordisk
32.18 Par Pharmaceuticals
32.19 PeptiDream
32.20 Roche
32.21 Sanofi
32.22 Tarix Pharmaceuticals
LIST OF FIGURES
Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 2-2: Layout of Advantages of Peptide Drugs
Figure 3-1: Classification Based over the Sources of Peptide
Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
Figure 4-1: Diagrammatic Representation of the Peptidic Probe
Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 5-3: Obesity - Estimated Prevalence by Country (2025)
Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US$)
Figure 5-5: Lantus – Monthly Cost Comparison by Country (US$)
Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US$ Billion)
Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market
Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country
Figure 6-2: Global - Cancer Peptide Therapeutics Market (US$ Billion), 2014 & 2020
Figure 6 3: Global - Velcade Market Sales (US$ Billion)
Figure 6-4: US – Velcade Sales (US$ Billion), 2016 & 2022
Figure 6-5: Global - Kyprolis Revenues (US$ Billion), 2013 - 2017
Figure 6-6: Global & US - Zoladex Sales (US$ Million), 2016
Figure 7-1: Global & US - Angiomax Sales (US$ Million)
Figure 7-2: Global - Integrilin Sales (US$ Million), 2016
Figure 8-1: Global - Top 10 Leading Causes of Death
Figure 8-2: Global – HIV Prevalence among Varied Regions
Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2016
Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)
Figure 10-1: Global - Peptide Drug Market (US$ Billion), 2014-2022
Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration
Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
Figure 15-1: Future Trends of Peptide Therapeutics
Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 2-2: Layout of Advantages of Peptide Drugs
Figure 3-1: Classification Based over the Sources of Peptide
Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
Figure 4-1: Diagrammatic Representation of the Peptidic Probe
Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 5-3: Obesity - Estimated Prevalence by Country (2025)
Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US$)
Figure 5-5: Lantus – Monthly Cost Comparison by Country (US$)
Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US$ Billion)
Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market
Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country
Figure 6-2: Global - Cancer Peptide Therapeutics Market (US$ Billion), 2014 & 2020
Figure 6 3: Global - Velcade Market Sales (US$ Billion)
Figure 6-4: US – Velcade Sales (US$ Billion), 2016 & 2022
Figure 6-5: Global - Kyprolis Revenues (US$ Billion), 2013 - 2017
Figure 6-6: Global & US - Zoladex Sales (US$ Million), 2016
Figure 7-1: Global & US - Angiomax Sales (US$ Million)
Figure 7-2: Global - Integrilin Sales (US$ Million), 2016
Figure 8-1: Global - Top 10 Leading Causes of Death
Figure 8-2: Global – HIV Prevalence among Varied Regions
Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2016
Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)
Figure 10-1: Global - Peptide Drug Market (US$ Billion), 2014-2022
Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration
Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
Figure 15-1: Future Trends of Peptide Therapeutics
LIST OF TABLES
Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs
Table 2-2: Comparative Differentiation between Peptide & Protein Drugs
Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
Table 5-2: Layout of Insulin & its Analogs Cost in US
Table 6-1: Approved Commercialized Peptide Cancer Drugs
Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases
Table 8-1: Approved Drugs for Infections
Table 9-1: Brief Characterization of Some Neuroprotective Peptides
Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders
Table 11-1: List of Approved Peptide Drugs Since 2000
COMPANIES MENTIONED
Amgen
Amylin Pharmaceuticals
Apitope Technology
BioPartners
BiondVax Pharmaceuticals Ltd
Boehringer Ingelheim
Circassia
Corden Pharma (Peptisyntha)
Eli Lily
Galena Biopharmaceuticals
GlaxoSmithKline
Hyperion Therapeutics
ImmunoCellular Therapeutics
Ipsen
Lonza
Merck
NovoNordisk
Par Pharmaceuticals
PeptiDream
Roche
Sanofi
Tarix Pharmaceuticals
Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs
Table 2-2: Comparative Differentiation between Peptide & Protein Drugs
Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
Table 5-2: Layout of Insulin & its Analogs Cost in US
Table 6-1: Approved Commercialized Peptide Cancer Drugs
Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases
Table 8-1: Approved Drugs for Infections
Table 9-1: Brief Characterization of Some Neuroprotective Peptides
Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders
Table 11-1: List of Approved Peptide Drugs Since 2000
COMPANIES MENTIONED
Amgen
Amylin Pharmaceuticals
Apitope Technology
BioPartners
BiondVax Pharmaceuticals Ltd
Boehringer Ingelheim
Circassia
Corden Pharma (Peptisyntha)
Eli Lily
Galena Biopharmaceuticals
GlaxoSmithKline
Hyperion Therapeutics
ImmunoCellular Therapeutics
Ipsen
Lonza
Merck
NovoNordisk
Par Pharmaceuticals
PeptiDream
Roche
Sanofi
Tarix Pharmaceuticals
